GlaxoSmithKline Pharmaceuticals Ltd
GLAXOBSE 500660PharmaceuticalsMkt cap ₹47,002 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹938 Cr
YoY +16.6%QoQ -5.7%
Net profit · Q1 FY27
₹237 Cr
YoY +15.7%QoQ -14.6%
Net margin · Q1 FY27
25.3%
-0.2 pts vs Q1 FY26
Net profit · FY26
₹1,036 Cr
YoY +11.7%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 938 | 995 | 1,041 | 980 | 805 | +16.6% |
| Other income | 43.76 | 35.95 | 32.12 | 33.57 | 43.72 | +0.1% |
| Total income | 982 | 1,031 | 1,073 | 1,014 | 849 | +15.7% |
| Profit before tax | 322 | 373 | 400 | 354 | 279 | +15.6% |
| Tax | 85.27 | 95.24 | 104 | 96.51 | 73.97 | +15.3% |
| Net profit | 237 | 278 | 296 | 257 | 205 | +15.7% |
| Net margin | 25.3% | 27.9% | 28.4% | 26.3% | 25.5% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 3,822 | 3,749 | 3,454 | 3,252 | 3,278 | +1.9% |
| Other income | 145 | 146 | 123 | 101 | 75.78 | -0.4% |
| Total income | 3,967 | 3,895 | 3,576 | 3,352 | 3,354 | +1.8% |
| Profit before tax | 1,406 | 1,260 | 816 | 836 | 779 | +11.6% |
| Tax | 370 | 332 | 226 | 229 | 398 | +11.4% |
| Net profit | 1,036 | 928 | 590 | 611 | 1,695 | +11.7% |
| Net margin | 27.1% | 24.7% | 17.1% | 18.8% | 51.7% |
BIC's take
We haven't covered GlaxoSmithKline Pharmaceuticals Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:36 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.